ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2027

Dysregulation of Granulopoiesis in Systemic Lupus Erythematosus

Neelakshi R. Jog1, Teresa Aberle 1, Cristina Arriens 2, Stefania Gallucci 3 and Judith James 2, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 3Lewis Katz School of Medicine, Temple University, Philadelphia, PA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: neutrophils and inflammation, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: SLE – Etiology & Pathogenesis Poster II

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by autoantibody production and periods of elevated disease activity. Recent studies indicate that along with dysfunctional adaptive immune responses, neutrophils are also important in disease pathogenesis. SLE patients have higher numbers of low-density granulocytes (LDGs) in peripheral blood that express neutrophil markers and are hyper-responsive to external stimuli. LDGs also have an enhanced ability to form neutrophil extracellular traps (NETs), and are suggested to be pathogenic in lupus. This study was carried out to determine whether the LDG fraction consists of immature cells and whether these cells differ with disease activity.

Methods: Peripheral blood mononuclear cells from 19 SLE patients with varying disease activity and 11 controls were enriched by density gradient centrifugation. Neutrophils were enriched by dextran sedimentation and density gradient centrifugation. LDG numbers were determined by flow cytometry. Plasma cytokines were measured by xMAP assays. Neutrophils were cultured for 3h and cytokines in supernatants were measured by xMAP assays. Levels of microRNA (miRNA) were determined by quantitative PCRs. SLE disease activity indices (SLEDAI) were obtained from medical records. Immature and mature neutrophil frequencies in bone marrow from 9-11 months old B6.NZM/Sle1/Sle2/Sle3 (Sle123) or C57BL/6J (B6) mice were determined by flow cytometry.

Results: SLE patients with elevated disease activity had significantly higher frequency of immature LDGs as determined by surface marker expression (p=0.0053) (Figure 1A). The frequencies of immature LDGs correlated with the SLE disease activity index (SLEDAI) and plasma G-CSF (Spearman r=0.651, p=0.0025, r=0.663, p=0.002, respectively) (Figure 1B). Compared to their wild type B6 counterpart, the spontaneous lupus mice Sle123 showed increased immature neutrophils (p=0.0079), similar to our data from lupus patients. SLE neutrophils spontaneously secreted higher levels of BAFF (p=0.043) and IL-21 (p=0.0394), but not IL-8 or MMP9. SLE neutrophils expressed significantly different levels of select miRNA compared to healthy neutrophils, as was previously reported for neutrophils generated by G-CSF induced emergency granulopoiesis.

Conclusion: Our data suggest that SLE patients may have dysregulated development of myeloid cells in the bone marrow due to the cytokine milieu present during elevated disease activity. The functional responses of these newly generated neutrophils may differ due to differences in the bone marrow transit time. The dysregulation of granulopoiesis therefore may generate neutrophils that further exacerbate autoimmune response.

Figure 1


Disclosure: N. Jog, None; T. Aberle, None; C. Arriens, AstraZeneca, 5, BMS, 2, 5, Exagen, 2, GSK, 2, 5; S. Gallucci, None; J. James, Abbvie, 5, Janssen, 5, Progentec, 2, Progentec Diagnostics, Inc., 2, Xencor, 2, Xencor, Inc., 2.

To cite this abstract in AMA style:

Jog N, Aberle T, Arriens C, Gallucci S, James J. Dysregulation of Granulopoiesis in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/dysregulation-of-granulopoiesis-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dysregulation-of-granulopoiesis-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology